Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 2:49:123-127.
doi: 10.1016/j.jor.2023.11.069. eCollection 2024 Mar.

Functional audit of the use of megaprosthesis for limb reconstruction in musculoskeletal tumors - A retrospective single-center study

Affiliations

Functional audit of the use of megaprosthesis for limb reconstruction in musculoskeletal tumors - A retrospective single-center study

Hawaibam Nongdamba et al. J Orthop. .

Abstract

Introduction: Medical advancements in musculoskeletal oncology has significantly reduced the mortality rate associated with limb-sparing surgery, making it comparable to amputation. The use of modular megaprosthesis for sarcoma treatment has now become a standard practice. However, these non-biological implants are not without their complications.

Materials and methods: A retrospective cohort study was conducted on all patients who underwent wide resection of locally aggressive and malignant bone tumors, followed by reconstruction with megaprosthesis between January 2018 and January 2023 at tertiary care hospital. Patients were evaluated based on oncological outcomes, functional outcomes, and complications with a minimum follow-up period of 6 months.

Results: The study included a total of 30 patients, comprising 16 males and 14 females, with a mean age of 33.6 ± 15.6 years. They all underwent wide resection and reconstruction with megaprosthesis. Diagnosis among the patients included 19 cases of giant cell tumors, 5 cases of osteosarcomas, 2 cases of metastatic bone tumors, and 1 case each of chondrosarcoma, malignant fibrous histiocytoma, multiple myeloma, and chondromyxoid fibroma. These tumors were predominantly located in the distal femur (15 patients) and proximal tibia (12 patients). The average follow-up period was 33 ± 21 months, resulting in an average final Musculoskeletal Tumor Society (MSTS) score of 81 % ± 9 %. Complications were observed in 21 patients, with infection being the most common, specifically Type 4 (10 patients, 37 %), followed by Type 1 (4 patients, 13 %) and Type 3 (4 patients, 13 %). Two patients (7 %) experienced Type 5 complications, while three succumbed to their illnesses. Additionally, two patients required amputation, one due to local recurrence and the other due to a deep-seated infection.

Conclusion: Megaprosthesis is a viable reconstruction option following wide resection of bone tumors. Infection remains the most common issue, and cost poses a significant challenge.

Keywords: Benign aggressive bone tumor; Limb salvage surgery; Malignant bone tumor; Megaprosthesis.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Fig. 1
Fig. 1
A: Clinical image depicting the deformity due to implant failure (type 3 Failure) B: Pre operative radiographs depicting the implant failure C: Intra operative image post reconstruction D: Image representing implant failure E: Post operative radiographs F, G : 6 months post op follow up radiograph.
Fig. 2
Fig. 2
A: Pie chart depicting Distribution of complications among surgery patients 1 : Type 1 failure, 3 : Type 3 failure, 4 : Type 4 failure, 5 : Type 5 failure B: Pie chart depicting distribution of complication s in patients who underwent ditsal femur megaprosthesis surgery; 1 : Type 1 failure, 3 : Type 3 failure, 4 : Type 4 failure C: Pie chart depicting distribution of complication s in patients who underwent proxima tibia megaprosthesis surgery; 1 : Type 1 failure, 3 : Type 3 failure, 4 : Type 4 failure.
Fig. 3
Fig. 3
1 : Pre op clinical photographs of bilateral lower limb 2 a: Pre operative magnestic resonace imaging sections representing hypo intense and hyperintensive osteosarcoma lesion involving proximal tibia left side 2 b: Pre operative radiographs suggestive of osteo sarcoma left proximal tibia 3 a: Intra operative image of wide resection of tumor involving proximal tibia 3 b: Intra operative image of mega prosthesis implantation 3 c: Intra operative image of medial gastroneumius flap for coverage 4 a: Immediate post op radiographs 4 b: Six months followup radiographs with implant in situ.

Similar articles

Cited by

References

    1. Özger H., Alpan B., Salduz A., et al. Mid-term implant survival, functional and radiological results and mechanical complications of mega-prosthetic reconstruction around the knee with the PENTA® system. Arch Orthop Trauma Surg. 2022 Sep;142(9):2323–2333. doi: 10.1007/s00402-021-04108-3. Epub 2021 Aug 21. PMID: 34417851; PMCID: PMC9381614. - DOI - PMC - PubMed
    1. Bacci G., Ferrari S., Bertoni F., et al. Longterm outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–4027. - PubMed
    1. Bacci G., Ferrari S., Comandone A., Zanone A., Ruggieri P., Longhi A., Bertoni F., Forni C., Versari M., Rimondini S. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39:111–116. - PubMed
    1. Bacci G., Picci P., Ferrari S., et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma for the extremities: the recent experience at the Rizzoli Institute. Cancer Treat Res. 1993;62:299–308. - PubMed
    1. Bacci G., Picci P., Ferrari S., et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227–3238. - PubMed

LinkOut - more resources